Adjuvant Chemotherapy in Head and Neck Cancer

Defining High-Risk Disease Requiring Adjuvant Chemoradiotherapy

The National Comprehensive Cancer Network (NCCN) recommends adjuvant concurrent chemoradiotherapy for patients with resected high-risk head and neck squamous cell carcinoma, specifically those with extracapsular nodal spread and/or positive surgical margins (<5 mm), as the standard of care 1, 2, 3
Extracapsular nodal spread from lymph nodes is an absolute indication for adjuvant chemoradiotherapy, not just radiotherapy alone, according to the NCCN guidelines 1, 2, 4
Positive or close surgical margins (defined as <5 mm) are also an absolute indication for adjuvant chemoradiotherapy, as per the NCCN guidelines 1, 2, 4

The evidence-based regimen consists of cisplatin 100 mg/m² intravenously every 3 weeks for 3 cycles, concurrent with conventional fractionation radiotherapy, as recommended by the NCCN 1, 2, 3
Alternative dosing of cisplatin 50 mg weekly has also shown survival benefit in randomized trials, according to the NCCN guidelines 1, 2

For patients who cannot tolerate cisplatin, the NCCN suggests considering docetaxel (15 mg/m² weekly) plus cetuximab (400 mg/m² loading, then 250 mg/m² weekly) plus radiotherapy, based on the phase 2 RTOG 0234 study 4
Carboplatin-based regimens may be considered, although they lack robust evidence, as noted in the Cancer Treatment Reviews 5, 6, 4

A margin of <5 mm is considered "close" and warrants adjuvant chemoradiotherapy, according to the Cancer Treatment Reviews 4
The NCCN guidelines suggest that margins ≥1 mm may not significantly impact overall survival, but the conservative approach is to treat margins <5 mm with chemoradiotherapy when combined with other risk factors 4

Concurrent chemoradiotherapy carries substantial toxicity, including grade 3-4 mucositis, lymphopenia, leukopenia, dysphagia, and neutropenia, as reported in the Journal of the National Comprehensive Cancer Network 2, 3
The NCCN recommends that this treatment should only be administered by experienced multidisciplinary teams with robust supportive care infrastructure 3